Santen Pharmaceutical Co., Ltd.: Hypertension trials

The registry lists 34 Hypertension studies with Santen Pharmaceutical Co., Ltd. as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 4Phase 2 13Phase 3 18Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT04742283Phase 2Results posted
• A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT04133311Phase 3Results posted
• Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6CompletedNCT03858894Phase 2Results posted
• DE-117 Spectrum 5 StudyCompletedNCT03697811Phase 3Results posted
• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyCompletedNCT03691662Phase 3Results posted
• A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyCompletedNCT03691649Phase 3Results posted
• A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel StudyCompletedNCT03216902Phase 2Results posted
• A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHTCompletedNCT02981446Phase 3Results posted
• DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionCompletedNCT01343082Phase 3Results posted
• DE-111 Against Timolol Ophthalmic Solution 0.5%CompletedNCT01342094Phase 3Results posted
• DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%CompletedNCT01342081Phase 3Results posted
• Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved FormulationCompletedNCT00918346Phase 3Results posted
• A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular HypertensionCompletedNCT05503901Phase 3
• A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedNCT05495061Phase 3
• Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag IsopropylStatus unknownNCT05279716Phase 4
• Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World SettingCompletedNCT04828057
• Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)CompletedNCT04737928Not applicable
• A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular HypertensionCompletedNCT03822559Phase 3
• A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI StudyCompletedNCT02822742Phase 3
• A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE StudyCompletedNCT02822729Phase 3
• A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-CompletedNCT02623738Phase 2/3
• Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT02179008Phase 2
• A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedNCT02102750Phase 1
• Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular HypertensionCompletedNCT01868126Phase 2
• A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTCompletedNCT01654484Phase 1/2
• Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant AdministrationsCompletedNCT01306461Phase 3
• Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against MonotherapiesCompletedNCT01292460Phase 3
• Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT01279083Phase 1/2
• Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface DiseaseCompletedNCT01254370Phase 2
• Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye DropsCompletedNCT01087671Phase 3
• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular HypertensionCompletedNCT00868894Phase 1/2
• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00657579Phase 2
• To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00656240Phase 2
• Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular HypertensionCompletedNCT00650338Phase 2